• Vaccine Name: Influenza virus HA protein vaccine (Influenza A virus (A/Yamagata/120/1986(H1N1)))
• Target Pathogen: Influenza virus
• Target Disease: Influenza (flu)
• Vaccine Ontology ID: VO_0004017
• Type: Subunit vaccine
• Status: Research
• Antigen: Influenza A virus (A/Yamagata/120/1986(H1N1)) HA hemagglutinin
• HA gene engineering:
  • Type: Recombinant protein preparation
  • Description: HA vaccines were prepared from influenza viruses A/PR/8/34 (H1NI), A. Yamagata/120/86 (HINI), A/ Fukuoka/C29/85 (H3N2) and B/Ibaraki/2/85 by the method of Davenport et al. in the Kitasato Institute, Tokyo, Japan (Tamura et al., 1989).
    
    Davenport, FM., Hennessy, A.V., Brandon, F.M., Webster, R.G.,Barrett, C.D. Jr. and Lease, G.O. Comparisons of serologic andfebrile responses in human to vaccination with influenza A viruses ortheir hemagglutinins. J. Lab. Clin. Med. 1964, 63, 5
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001242
• Immunization Route: Intranasal

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were anaesthetized by an intraperitoneal injection of amobarbital sodium (0.25 ml of a solution of 1 p.g ml-1) and then immunized by an
  intranasal inoculation of 10lal phosphate-buffered saline (PBS) containing the required dose of HA vaccine and CTB (Tamura et al., 1989).
• Challenge Protocol: Viral challenge four weeks after intranasal inoculation (Tamura et al., 1989).
• Efficacy: The inoculation of HA vaccine prepared from influenza viruses A/Yamagata/120/86 (H1N1) or A/Fukuoka/C29/85 (H3N2) together with CTB provided partial protection against PR-8 infection in Balb/c mice (Tamura et al., 1989).